Anteris’s DurAVR Targets $10B TAVR Market with New Balloon-Expandable Valve
Anteris Technologies has developed DurAVR, a single-piece, balloon-expandable transcatheter aortic valve using proprietary ADAPT tissue, targeting a $10B global TAVR market by 2028. The device aims to combine ease of use, like Edwards’ balloon-expandable Sapien, with haemodynamic performance superior to Medtronic’s self-expanding Evolut.
1. Market Opportunity and Unmet Patient Needs
Anteris is targeting the global transcatheter aortic valve replacement market projected at $10 billion by 2028, driven by expanded use in lower-risk, younger patients. Existing Sapien and Evolut systems leave many patients with suboptimal haemodynamics and durability issues, creating a growing valve-in-valve replacement segment.
2. DurAVR Design Innovation
DurAVR features a single-piece, moulded ADAPT tissue valve designed from scratch to mimic native valve mechanics, combining a balloon-expandable delivery system for procedural ease with haemodynamic performance that rivals or exceeds self-expanding alternatives.
3. Strategic Implications for Anteris
By addressing clinician demand for ease of use and curative haemodynamics, Anteris aims to capture share from Edwards and Medtronic; successful development and approval of DurAVR could propel revenue growth and establish the company as a third major TAVR competitor.